Wednesday, 22 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 22 January 2025
News

Govt biosim spend jumps 13.5%

Posted 17 January 2025 AM

New analysis shows the federal government spent just over $197 million on biosimilars in the 2023-24 financial year, a 13.5 per cent year-on-year increase.

Pharma in Focus compared biosimilar data from the 2022-23 FY and the 2023-24 FY PBS Expenditure and Prescriptions reports, which rank biosimilar brands by highest cost to government and excludes the Efficient Funding of Chemotherapy program.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (14)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.